Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider

被引:46
作者
Tripto-Shkolnik, Liana [1 ]
Fund, Naama [2 ]
Rouach, Vanessa [3 ]
Chodick, Gabriel [2 ,4 ]
Shalev, Varda [2 ,4 ]
Goldshtein, Inbal [2 ]
机构
[1] Chaim Sheba Med Ctr, Div Endocrinol Diabet & Metab, Tel Hashomer, Israel
[2] Maccabi Healthcare Serv, Maccabitech Inst Res & Innovat, Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Inst Endocrinol Metab & Hypertens, Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
关键词
Osteoporosis; Vertebral fractures; Treatment discontinuation; Denosumab discontinuation; VERTEBRAL FRACTURES; POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; EXPOSURE; THERAPY; RISK;
D O I
10.1016/j.bone.2019.115150
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Vertebral fractures (VF) upon Denosumab (DMAB) discontinuation were first described as a distinct phenomenon in 2015, yet the magnitude of this event remains undetermined. Objectives: To estimate fracture risk after DMAB discontinuation, in a real-world setting. Methods: The computerized database of a 2.3-million members' state-mandated health organization was utilized to detect osteoporotic patients with at least two DMAB dispenses. Treatment discontinuation was defined as a refill gap of 3 months or more, while the discontinuation date was defined as an anticipated missed purchase date. Fractures were identified by an osteoporosis registry and individually adjudicated by an expert's review. Fractures occurring within one year from discontinuation among DMAB discontinuers (DD) and from the 2nd year of treatment onwards for persistent users (PU) were included. Results: A total of 1500 DD (92% females, mean +/- SD age = 71.8 +/- 9.5y), and 1610 PU (91%, 71.7 +/- 8.8) were identified. At baseline, the groups were comparable in fracture- history, bisphosphonate exposure, smoking, and bone density. Multiple VF occurred in 12 (0.8%) DD vs. 2 (0.1%) PU (p = 0.006). The overall rate of fractures per 100 patient-years of follow-up was significantly higher in DD than PU (RR 3.2, 95% CI 2.2-4.8), as well as the rate of VF (RR 4.7, 95% CI 2.3-9.6) and multiple VF (RR 14.6, 95% CI 3.3-65.3, effect size 1.06). Conclusions: Patients who discontinue DMAB are at greater risk of major OP fractures than those who persist with treatment. Same is true for clinical multiple vertebral fractures, yet the incidence of the latter was low. These findings demonstrate a need for greater awareness and thoughtful management of DMAB discontinuation.
引用
收藏
页数:7
相关论文
共 30 条
[11]   Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension [J].
Cummings, Steven R. ;
Ferrari, Serge ;
Eastell, Richard ;
Gilchrist, Nigel ;
Jensen, Jens-Erik Beck ;
McClung, Michael ;
Roux, Christian ;
Torring, Ove ;
Valter, Ivo ;
Wang, Andrea T. ;
Brown, Jacques P. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (02) :190-198
[12]   Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis [J].
Cummings, Steven R. ;
San Martin, Javier ;
McClung, Michael R. ;
Siris, Ethel S. ;
Eastell, Richard ;
Reid, Ian R. ;
Delmas, Pierre ;
Zoog, Holly B. ;
Austin, Matt ;
Wang, Andrea ;
Kutilek, Stepan ;
Adami, Silvano ;
Zanchetta, Jose ;
Libanati, Cesar ;
Siddhanti, Suresh ;
Christiansen, Claus .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :756-765
[13]  
GOLDSHTEIN I, 2015, J AGING RES CLIN PRA, V4, P1
[14]   Effects of Denosumab on Fracture and Bone Mineral Density by Level of Kidney Function [J].
Jamal, Sophie A. ;
Ljunggren, Osten ;
Stehman-Breen, Catherine ;
Cummings, Steven Ron ;
McClung, Michael R. ;
Goemaere, Stefan ;
Ebeling, Peter R. ;
Franek, Edward ;
Yang, Yu-ching ;
Egbuna, Ogo I. ;
Boonen, Steven ;
Miller, Paul D. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (08) :1829-1835
[15]   Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials [J].
Kim, Tiffany Y. ;
Bauer, Douglas C. ;
McNabb, Brian L. ;
Schafer, Anne L. ;
Cosman, Felicia ;
Black, Dennis M. ;
Eastell, Richard .
JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (05) :810-816
[16]   Underestimation of Vertebral Fractures After Denosumab Discontinuation [J].
Lamy, Olivier ;
Gonzalez-Rodriguez, Elena .
JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (03) :547-547
[17]   Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report [J].
Lamy, Olivier ;
Gonzalez-Rodriguez, Elena ;
Stoll, Delphine ;
Hans, Didier ;
Aubry-Rozier, Berengere .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (02) :354-358
[18]   Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD [J].
Lewiecki, E. Michael ;
Miller, Paul D. ;
McClung, Michael R. ;
Cohen, Stanley B. ;
Bolognese, Michael A. ;
Liu, Yu ;
Wang, Andrea ;
Siddhanti, Suresh ;
Fitzpatrick, Lorraine A. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (12) :1832-1841
[19]   Cancel the denosumab holiday [J].
McClung, M. R. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (05) :1677-1682
[20]   Denosumab in postmenopausal women with low bone mineral density [J].
McClung, MR ;
Lewiecki, EM ;
Cohen, SB ;
Bolognese, MA ;
Woodson, GC ;
Moffett, AH ;
Peacock, M ;
Miller, PD ;
Lederman, SN ;
Chesnut, CH ;
Lain, D ;
Kivitz, AJ ;
Holloway, DL ;
Zhang, C ;
Peterson, MC ;
Bekker, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :821-831